MARKET

VYGR

VYGR

Voyager
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.32
-0.19
-1.31%
Closed 16:33 11/21 EST
OPEN
14.60
PREV CLOSE
14.51
HIGH
14.67
LOW
13.96
VOLUME
272.65K
TURNOVER
--
52 WEEK HIGH
28.79
52 WEEK LOW
7.76
MARKET CAP
530.89M
P/E (TTM)
-8.8069
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VYGR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VYGR News

  • Neurocrine Making The Most Of A Strong Ingrezza Launch
  • Seeking Alpha - Article.1d ago
  • Neurocrine Bounces Back With Authority, But Little Upside Appears Evident As New Year Approaches
  • Seeking Alpha - Article.2d ago
  • Edited Transcript of VYGR earnings conference call or presentation 6-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.11/13 02:05
  • Gene Therapy Series 2: Delivery Systems In Gene Therapy, Including Viral Vectors
  • Seeking Alpha - Article.11/11 22:17

More

Industry

Biotechnology & Medical Research
-0.31%
Pharmaceuticals & Medical Research
+0.39%

Hot Stocks

Name
Price
%Change

About VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
More

Webull offers Voyager Therapeutics Inc (VYGR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.